🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Medincell SA (0ACH)

London
Currency in EUR
Disclaimer
14.86
+6.11(+69.83%)
Closed
0ACH Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
14.8414.86
52 wk Range
5.4017.38
Prev. Close
8.75
Open
14.84
Day's Range
14.84-14.86
52 wk Range
5.4-17.38
Volume
15
Average Volume (3m)
217
1-Year Change
140.84%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
0ACH Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
20.70
Upside
+40.82%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

People Also Watch

38.90
GRBT
-0.77%
15.30
JCQ
0.00%
5.44
ADOC
-3.72%
154.40
ESSF
+5.90%

Medincell SA Company Profile

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Employees
131
Market
France
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.